Skip to Main Content

A new analysis of the latest type of cholesterol-lowering drugs finds that prices would have to drop by more than two-thirds — to about $4,200 a year — for the medicines to be cost effective.

The findings were made after assessing discounted prices and results of a recent clinical trial that studied cardiovascular outcomes for one of the two available medicines, which are known as PCSK9 inhibitors. One drug is sold by Amgen (AMGN), while the other is marketed jointly by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN). The analysis was published in the Journal of the American Medical Association.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Ed, the best and most relevant argument for competition would be the statins. For example sales peaked at $10.8 billion for Lipitor in 2007 vs $5.2 billion for Zocor. The difference was two fold: 1) The superior Pfizer marketing machine, perhaps leading to 2) perceived better efficacy of lipitor

    Their are two complementary scenarios possible with Repatha and Praluent 1) the “win-lose” outcome with as per above, or 2) the two companies won’t throw huge marketing budgets at the products, and in such case there will literally not a dime’s worth of difference in price between them.

Comments are closed.